期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Future clinical prospects of C-peptide testing in the early diagnosis of gestational diabetes
1
作者 Charalampos Milionis Ioannis Ilias +2 位作者 anastasia lekkou Evangelia Venaki Eftychia Koukkou 《World Journal of Experimental Medicine》 2024年第1期13-21,共9页
Gestational diabetes is typically diagnosed in the late second or third trimester of pregnancy.It is one of the most common metabolic disorders among expectant mothers,with potential serious short-and long-term compli... Gestational diabetes is typically diagnosed in the late second or third trimester of pregnancy.It is one of the most common metabolic disorders among expectant mothers,with potential serious short-and long-term complications for both maternal and offspring health.C-peptide is secreted from pancreatic beta-cells into circulation in equimolar amounts with insulin.It is a useful biomarker to estimate the beta-cell function because it undergoes negligible hepatic clearance and consequently it has a longer half-life compared to insulin.Pregnancy induces increased insulin resistance due to physiological changes in hormonal and metabolic homeostasis.Inadequate compensation by islet beta-cells results in hyperglycemia.The standard oral glucose tolerance test at 24-28 wk of gestation sets the diagnosis.Accumulated evidence from prospective studies indicates a link between early pregnancy C-peptide levels and the risk of subsequent gestational diabetes.Elevated C-peptide levels and surrogate glycemic indices at the beginning of pregnancy could prompt appropriate strategies for secondary prevention. 展开更多
关键词 C-PEPTIDE Gestational diabetes Secondary prevention PREGNANCY Clinical laboratory techniques
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部